(-)-(5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one | 1312671-81-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (-)-(5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one
• 英文别名: (5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4,4-dimethyl-1,3-oxazolidin-2-one
• CAS: 1312671-81-0
• 化学式: C₃₁H₂₇F₁₀NO₃
• 分子量: 651.544
• InChiKey: DCGKVWUPMGGBHY-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  45
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  N-苄氧羰酰基-2-甲基丙氨酸 在 N-甲基吗啉 、 sodium hydride 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 23.75h， 生成 (+)-(5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one 、 (-)-(5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib

  摘要：

  The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically, it was found that substitution of the 4-position with a methyl group with the cis-stereochemistry relative to the 5-aryl group afforded compounds with increased cholesteryl ester transfer protein (CETP) inhibition potency and a robust in vivo effect on increasing HDL-C levels in transgenic mice expressing cynomolgus monkey CETP.

  DOI：

  10.1021/jm200484c

文献信息

• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：DalCor Pharma UK Ltd Leatherhead, Zug Branch

  公开号：EP3833336A1

  公开（公告）日：2021-06-16
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS<br/>[FR] MÉTHODES DE TRAITEMENT OU DE PRÉVENTION DE TROUBLES CARDIOVASCULAIRES ET D'ABAISSEMENT DU RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES
  申请人：DALCOR PHARMA UK LTD STOCKPORT ZUG BRANCH

  公开号：WO2019043018A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES<br/>[FR] PROCÉDÉS POUR RETARDER L'APPARITION D'UN NOUVEAU DEBUT DE DIABÈTE DE TYPE 2 DE TYPE 2 ET POUR RALENTIR LA PROGRESSION ET TRAITER LE DIABÈTE DE TYPE 2
  申请人：DALCOR PHARMA UK LTD LEATHERHEAD ZUG BRANCH

  公开号：WO2020030814A1

  公开（公告）日：2020-02-13

  The invention provides compositions and methods useful for delaying occurrence of new- onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.